In 2001, imatinib was the first proof that small molecule inhibitors targeting molecular drivers of cancer could be an ...
US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia (CML) has raised questions due to the number of medications already available ...
Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...
Which medicine is best when you are affected by cancer? This can vary from person to person. A new method can help people with a specific type of blood cancer get the best medicine for them. "The new ...
At just 21, Amber Cunningham-Rogan began noticing bleeding gums, persistent fatigue, and a strange tingling sensation in her hands and legs. Initially, she assumed these were minor dental issues or ...
Accelerated-phase CML is characterized by faster progression than chronic phase, with variable symptom burden including fatigue, weight loss, night sweats, bruising, and splenic enlargement.
Assessment of long-term toxicities of imatinib in CML: Experience from a tertiary care cancer centre in south India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results